Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

Circulation, Journal Year: 2023, Volume and Issue: 149(1), P. 48 - 66

Published: Sept. 25, 2023

Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination and inhibition. often fulminant pathologically characterized by myocardial infiltration T lymphocytes macrophages. Although much has been learned about role T-cells in myocarditis, little understood identity, transcriptional diversity, functions infiltrating

Language: Английский

---

Clinical and translational attributes of immune-related adverse events

Nature Cancer, Journal Year: 2024, Volume and Issue: 5(4), P. 557 - 571

Published: Feb. 15, 2024

Language: Английский

---

Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(7), P. 443 - 462

Published: Jan. 26, 2024

Language: Английский

---

Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: 26(10), P. 2055 - 2076

Published: Aug. 1, 2024

Language: Английский

---

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(12), P. 3100 - 3110

Published: Oct. 26, 2023

Language: Английский

---

Priorities in Cardio-Oncology Basic and Translational Science

JACC CardioOncology, Journal Year: 2023, Volume and Issue: 5(6), P. 715 - 731

Published: Sept. 27, 2023

Despite improvements in cancer survival, therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This led the growth of burgeoning field cardio-oncology, which aims advance health patients and survivors, through actionable translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present focused review on mechanisms that contribute common toxicities discussed at this meeting, ongoing international collaborative efforts improve patient outcomes, bidirectional challenges translating basic research care. We acknowledge there are many additional therapies significance but were not topics discussion symposium. hope symposium-based can highlight knowledge gaps priorities inform design future studies aim prevent mitigate disease survivors.

Language: Английский

---

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 5, 2024

Immune checkpoint inhibitors (ICIs) are specialized monoclonal antibodies (mAbs) that target immune checkpoints and their ligands, counteracting cancer cell-induced T-cell suppression. Approved ICIs like cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), its ligand PD-L1, lymphocyte activation gene-3 (LAG-3) have improved patient outcomes by enhancing anti-tumor responses. However, some patients unresponsive, others experience immune-related adverse events (irAEs), affecting organs the lung, liver, intestine, skin now cardiovascular system. These cardiac irAEs include conditions myocarditis, atherosclerosis, pericarditis, arrhythmias, cardiomyopathy. Ongoing clinical trials investigate promising alternative co-inhibitory receptor targets, including T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) immunoreceptor with ITIM domain (TIGIT). This review delves into mechanisms of approved (CTLA-4, PD-1, LAG-3) upcoming options Tim-3 TIGIT. It explores use in treatment, supported both preclinical data. Additionally, it examines behind toxic irAEs, focusing on ICI-associated myocarditis atherosclerosis. insights vital as continue to revolutionize therapy, offering hope patients, while also necessitating careful monitoring management potential side effects, emerging complications.

Language: Английский

---

Toxicity in the era of immune checkpoint inhibitor therapy

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 23, 2024

Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting co-inhibitory molecules such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4). Although ICIs have had unprecedented success become the standard of care for many cancers, they are often accompanied off-target inflammation that can occur in any organ system. These related adverse events (irAEs) require steroid use and/or cessation ICI therapy, which both lead to cancer progression. irAEs common, detailed molecular mechanisms underlying their development still elusive. To further our understanding develop effective treatment options, there is pressing need preclinical models recapitulating clinical settings. In this review, we describe current implications ICI-induced skin toxicities, colitis, neurological endocrine pneumonitis, arthritis, myocarditis along with management.

Language: Английский

---

Autoimmune Myocarditis, Old Dogs and New Tricks

Circulation Research, Journal Year: 2024, Volume and Issue: 134(12), P. 1767 - 1790

Published: June 6, 2024

Autoimmunity significantly contributes to the pathogenesis of myocarditis, underscored by its increased frequency in autoimmune diseases such as systemic lupus erythematosus and polymyositis. Even cases myocarditis caused viral infections, dysregulated immune responses contribute pathogenesis. However, whether triggered existing conditions or precise antigens immunologic pathways driving remain incompletely understood. The emergence associated with checkpoint inhibitor therapy, commonly used for treating cancer, has afforded an opportunity understand mechanisms autoreactive T cells specific cardiac myosin playing a pivotal role. Despite their self-antigen recognition, myosin-specific can be present healthy individuals due bypassing thymic selection stage. In recent studies, novel modalities suppressing activity pathogenic including have proven effective myocarditis. This review offers overview current understanding heart antigens, autoantibodies, underlying various forms along latest updates on clinical management prospects future research.

Language: Английский

---

Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart

Nature reviews. Cancer, Journal Year: 2024, Volume and Issue: 24(8), P. 540 - 553

Published: July 9, 2024

Language: Английский

---